Clinical and microbiological features of atopic dermatitis in HIV-positive patients (literature review)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis (AtD) is a chronic, recurrent, multifactorial, inflammatory skin disease, which is characterized by skin itching, the formation of foci of lichenification in places of chronic skin inflammation. The review article presents data from studies carried out on different continents of the world regarding differences in the course of AtD in patients with and without HIV infection. According to researchers, to date the incidence of AtD has increased several times since the 1960s, and it occurs in 20% of children and 3% of adults, more often in women than in men. At the same time, the prevalence and severity of the course of AtD is higher in industrialized cities relative to rural areas. In HIV-infected patients, AtD is recorded 30% more often than in the population; attention is also paid to some pathogenetic features of the disease in patients of this category [3]. Differences in individual immunological aspects of the pathogenesis of AtD associated with the influence of HIV virus proteins on immunocompetent cells of patients are noted. Further, modern studies on the effect of skin and intestinal microbiota on the course of AtD, their features in HIV-positive and HIV-negative patients are presented. In addition to the clinical features of AtD, fundamental issues of diagnosis and treatment of AtD accepted to date are also discussed.

Full Text

Restricted Access

About the authors

E. Yu Evdokimov

Central Research Institute of Epidemiology

Email: evdokimovevg@yandex.ru
Cand. Sci. (Med.), Researcher at the Clinical Department

Zh. B Ponezheva

Central Research Institute of Epidemiology

A. V Sundukov

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

E. V Svechnikova

Outpatient Clinic № 1 of the Administrative Department of the President of the Russian Federation

References

  1. Drucker A.M., Wang A.R., Li W.-Q, et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. J Invest Dermatol. 2017;1:26-30. doi: 10.1016/j.jid.2016.07.012.
  2. Вольф К., Голдсмит Л.А., Кац С.И. и др. Дерматология Фицпатрика в клинической практике. Пер. с англ. М., 2012;1(868):155-68.
  3. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(Supp. 1):8-16. doi: 10.1159/000370220.
  4. Odhiambo J.A, Williams H.C., Clayton T.O., et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-58.
  5. Mallol J., Crane J., von Mutius E., et al. ISAAC Phase Three Study Group: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr.) 2013;41:733-85.
  6. Barbarot S., Auziere S., Gadkari A., et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-93. doi: 10.1111/all.13401. [Epub ahead of print].
  7. Siberry G.K., leister E., Jacobson D., et al. Increased risk of asthma and atopic dermatitis in perinatally HIV-infected children and adolescents. Clin Immunol. 2012;142(2):201-8.
  8. Абрамовитс У., Акхаван А., Альтчек Д. и др. Атопический дерматит и экзематозные расстройства. Под ред. Д. Рудикоффа и др. Пер. с англ. Под ред. Н.Н. Потекаева, А.Н. Львова. М., 2017. 380 с. [Abramovits U., Akhavan A., Altchek D. et al. Atopic dermatitis and eczematous disorders. Ed. by D. Rudikoff, et al. Translation from English. Ed. by N.N. Potekaev, A.N. Lvov M., 2017. 380 p. (In Russ.)].
  9. Elmose C., Thomsen S.F Twin Studies of Atopic Dermatitis: Interpretations and Applications in the Filaggrin Era. J Allergy. 2015. Article ID 902359:7. doi: 10.1155/2015/902359.
  10. Lianghua Bin, Donald YM. Leung Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma Clin Immunol. 2016;12:52.
  11. Sandilands A, Sutherland C., Irvine A., et al. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009;122:1285-94.
  12. Brown S.J, McLean WH. One remarkable molecule: filaggrin. J Invest Dermatol. 2012;132:751-62.
  13. Van den Oord R.A., Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. Br Med J. 2009;339:1-12.
  14. Brown S.J., Relton C.L., Liao H., et al. Filaggrin null mutations and childhood atopic eczema: a population-based case-control study. J Allergy Clin Immunol. 2008;121:940-46.
  15. Polcari I., Becker L., Stein S.L., et al. Filaggrin gene mutations in African Americans with both ichthyosis vulgaris and atopic dermatitis. Pediatr Dermatol. 2014;31(4):489-92.
  16. Wozniak M., Kaczmarek-Skamira E., Roman ska-Gocka K., et al. The prevalence of mutations in the gene encoding filaggrin in the population of Polish patients with atopic dermatitis. Postepy Dermatol Alergol. 2016;33(2):128-33.
  17. Osawa R., Akiyama M., Shimizu H. Filaggrin gene defects and the risk of developing allergic disorders. Allergol Int. 2011;60:1-9.
  18. Marukian N.V, Choate K.A. Recent advances in understanding ichthyosis pathogenesis. Published on-line 2016 Jun 24. Doi: 10.12688/ f1000research.8584.1.
  19. Kisich K.O., Carspecken C.W., Fieve S., et al. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol. 2008;122(1):62-8.
  20. Li Z., Levast B., Madrenas J. Staphylococcus aureus downregulates IP-10 production and prevents Th1 cell recruitment. J Immunol. 2017;198(5):1865-74.
  21. Freeman M.L., Shive C.L., Nguyen TP., et al. Cytokines and T-Cell Homeostasis in HIV Infection. J Infect Dis. 2016;214(Suppl. 2):S51-7. doi: 10.1093/mfdis/jiw287.
  22. Mhatre M., McAndrew T, Carpenter C., et al. Cervical intraepithelial neoplasia is associated with genital tract mucosal inflammation. Sex Transmit Dis. 2012;39(8):591-97.
  23. Pace B.T., Lackner A.A., Porter E., Pahar B. The Role of Defensins in HIV Pathogenesis. Mediat Inflamm. 2017;2017:5186904.
  24. Shet A., Mathema B., Mediavilla J.R., et al. Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis. 2009;200(1):88-93.
  25. Kong H.H., Oh J., Deming C., et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;22(5):850-59.
  26. Hill D.A., Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Ann Rev Immunol. 2010;28:623-67.
  27. Schroeder B.O., Bäckhed F. Signals from the gut microbiota to distant organs in physiology and dise. ase. Nat Med. 2016;22(10):1079-89.
  28. O'Neill C.A., Monteleone G., McLaughlin J.T., Paus R. The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays. 2016;38(11):1167-76.
  29. Miyazaki K., Masuoka N., Kano M., Iizuka R. Bifidobacterium fermented milk and galactooligosaccharides lead to improved skin health by decreasing phenols production by gut microbiota. Benef Microbes. 2014;5(2):121-28.
  30. Kosiewicz M.M., Dryden G.W., Chhabra A., Alard P Relationship between gut microbiota and development of T cell associated disease. FEBS Letters. 2014;588(22):4195-206.
  31. Lindberg M., Söderquist B. Atopic dermatitis and gut microbiota. Br J Dermatol. 2017;176(2):297-98.
  32. Song H., Yoo Y, Hwang J., et al. Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. J Allergy Clin Immunol. 2016;137(3):852-60.
  33. Gootenberg D.B., Paer J.M., Luevano J.M., Kwon D.S. HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammation. Curr Opin Infect Dis. 2017;30(1):31-43.
  34. Wei Lu, Yuqing Feng, Fanhui Jing, et al. Association Between Gut Microbiota and CD4 Recovery in HIV-1 Infected Patients. Front Microbiol. 2018;9:1451.
  35. Imlay H., Kau D., Rao K. Risk factors forClostridium difficile infection in HIV-infected patients. SAGE Open Med. 2016;4:2050312116684295.
  36. Kim K.H. Overview of atopic dermatitis. Asia Pac Allergy. 2013;3(2):79-87. Doi: 10.5415/ apallergy. 2013.3.2.7.
  37. Williams H.C., Burney PG., Hay R.J., et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br. J. Dermatol. 1994;131(3):383-96.
  38. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force Atopic Dermatitis. Dermatol. (Basel). 1993;186(1):23-31.
  39. Hanifin J.M., Thurston M., Omoto M., et al. The eczema Area and Severity index (EASI): assessment reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-8.
  40. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol. 1996;135(Suppl. 48):25-30.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies